Semaglutide - Generic Peptides

Buy Semaglutide by Generic Peptides at XSteroids. Semaglutide is the GLP-1 receptor agonist peptide best known under the brand names Ozempic, Wegovy and Rybelsus. Generic Peptides lists it as a lyophilized powder in 2 mg, 5 mg and 10 mg vials, and this page explains what the molecule does, how the three vial sizes calculate, and where the line sits between the licensed medicine and the research vial sold here.

Two facts frame everything below. Semaglutide is an approved prescription drug in several manufactured forms; the lyophilized vial is not one of those forms, so it has no approved label, no approved indication and no validated shelf life. Nothing here is a dosing or treatment recommendation.

What Semaglutide by Generic Peptides Is and What You Are Buying

A semaglutide vial from Generic Peptides is a small glass vial holding a white lyophilized powder. The pack is a single vial, and the strength printed on the option you choose is the total in that vial: 2 mg, 5 mg or 10 mg. Bacteriostatic water is not included, because the diluent is a separate catalog item. The powder must be dissolved before any laboratory use.

The molecule itself is a synthetic peptide that copies the human gut hormone GLP-1, short for glucagon-like peptide-1. It was developed by Novo Nordisk and first approved in the United States in 2017. The injectable form became one of the most prescribed medicines in the world, and the oral tablet Rybelsus carries the same molecule in a special absorption-enhanced tablet. Generic Peptides documents semaglutide and the milligram figure on the box, but there is no published filler list for these research vials and no independent laboratory confirmation of the stated potency, so this page repeats only what the supplier puts in writing.

What you are buying is the active substance in a research format, not a manufactured pen and not a tablet. The physical form and the regulatory status are not the same as the licensed product.

How Semaglutide Works in the Body

Incretin action at the GLP-1 receptor

Semaglutide binds the GLP-1 receptor, a G-protein coupled receptor found on pancreatic beta cells, in the gut, in the brain and elsewhere. Binding raises cyclic AMP inside the cell and produces three practical effects: glucose-dependent insulin release, slower emptying of the stomach, and a reduction in the amount of food eaten. Those three effects, not tissue building, are why the compound sits in a fat loss category. It is not a steroid and it is not growth hormone.

The appetite signal runs through the hypothalamus and the brainstem, which is why the effect on hunger is described as central rather than local. The insulin effect only appears when glucose is already elevated, which is the meaning of the term glucose-dependent.

Once-weekly duration

A fatty side chain lets the peptide bind albumin, and that is what stretches the half-life to roughly one week in the approved form. After the last injection the substance is still detectable in the blood for several weeks, which is why the licensed products use a single weekly dose and why the effect tapers rather than stops. In people with obesity the apparent clearance is low, so the molecule accumulates over the first weeks of treatment.

What to Expect from Semaglutide Research

The clearest human data comes from the STEP programme. In STEP-1, published in 2021, 1961 adults without diabetes received 2.4 mg weekly for 68 weeks alongside a lifestyle programme, and average weight change was about 14.9 percent against 2.4 percent on placebo. Additional analyses reported improvements in blood pressure, lipids and inflammatory markers, and a large cardiovascular trial in people with established heart disease found fewer major cardiovascular events on the drug.

Those figures describe an approved product used under supervision. The timeline is months, not days: appetite changes appear in the first weeks, but the full weight effect builds over 68 weeks as the dose is stepped up no faster than every four weeks. Nausea and other gut effects cluster around each dose increase and usually settle.

Withdrawal is the part most people underestimate. In the extension of the main trial, participants who stopped regained roughly two thirds of the weight they had lost within the next year, and on average returned to their starting weight in about eighteen months. Part of the cardiometabolic improvement also reversed. Weight regain is not a failure of the vial; it is what the published data shows, and this page does not promise an outcome.

Semaglutide Vial Sizes, Dosing and Reconstitution

Three pack sizes

Dissolved with 1 ml of bacteriostatic water, a 2 mg vial gives 2 mg per ml, so 0.25 mg reads as 12.5 units on a U-100 syringe and 1 mg as 50 units. The 5 mg vial with 1 ml gives 5 mg per ml, where 0.25 mg is 5 units and 1 mg is 20 units. The 10 mg vial with 2 ml gives 5 mg per ml and the same readings as the 5 mg vial. Add the water slowly down the wall of the vial and swirl; do not shake a peptide.

Counting doses

A 2 mg vial holds eight 0.25 mg steps, a 5 mg vial holds twenty and a 10 mg vial holds forty. At the 2.4 mg maintenance figure used by the weight management product, a 10 mg vial covers about four doses, which shows that these are research pack sizes rather than a copy of a treatment course.

Label dose ladder

For reference only, the approved injectable starts at 0.25 mg once weekly for four weeks, then 0.5 mg, then 1 mg, and up to 2 mg. The weight management injectable moves through 0.25, 0.5, 1, 1.7 and 2.4 mg with at least four weeks per step. Those figures belong to manufactured pens, not to a research vial, and there is no approved titration for a lyophilized research product.

Stacking Semaglutide with Metabolic Peptides

There is no established combination protocol for these research vials, and every human dataset was collected on a single approved drug with a lifestyle programme alongside it. Readers often compare the class with Tirzepatide 5 mg, a dual GIP and GLP-1 agonist, or with Retatrutide 5 mg, an investigational triple agonist. Other fat loss options on the same shelf work through different routes: AOD 9604 2 mg and HGH Frag 176-191 2 mg are fragments studied for fat metabolism, and Adipotide 5 mg is an experimental compound with no approval. Tesamorelin 2 mg and NAD+ 100 mg sit in adjacent research areas. None of these pairings has been formally studied together.

Recovery and Post-Cycle Context for Semaglutide

Because the drug slows stomach emptying and reduces intake, coming off it is followed by a return of appetite and, in most people, weight regain. The withdrawal data above is the honest recovery picture. There is no post-cycle protocol for a GLP-1 research vial, because the class is not suppressive to the hormonal axis in the way anabolic compounds are, and no recovery regimen has been validated for it. If hunger returns quickly after stopping, that is the expected pharmacology rather than a fault in the product.

Semaglutide Side Effects and Safety Notes

Reported effects

Nausea, vomiting, diarrhoea, constipation and abdominal pain are the most common reactions. They are dose dependent and they cluster during dose increases. Because the drug slows stomach emptying, heartburn, dyspepsia and, rarely, gastroparesis are also reported, and gallbladder disease is a recognised risk. Resting heart rate has been seen to creep up by roughly three beats per minute.

Label warnings

A boxed warning sits on the approved products for thyroid C-cell tumours observed in rodents, and use is ruled out where medullary thyroid cancer or MEN-2 appears in the personal or family history. Across the class as a whole, pancreatitis warnings were tightened by regulators during 2026.

Anti-doping status

GLP-1 agonists are not on the WADA prohibited list and no exemption is required, but WADA has placed the class in its monitoring programme to decide whether that should change in future. The accurate wording is that no prohibition is published.

Storage of the Semaglutide Vial

Keep the lyophilized powder at 2 to 8 C, or in the freezer for longer storage. Once dissolved, keep the solution at 2 to 8 C and use it within about 28 days, and never freeze it. Those are research peptide conventions rather than label directions, because the vial has no approved label.

Why Buy Semaglutide Vials from XSteroids?

Buying Semaglutide from Generic Peptides at XSteroids gives you a clearly labelled research vial in 2 mg, 5 mg or 10 mg with the pack data shown on this page. Checkout is secure, US domestic shipping takes 3 to 6 days and international delivery 12 to 26 days. We keep the licensed medicines and the research vial separate, so you always know which product form you are ordering.